Drug Type Biosimilar, Monoclonal antibody |
Synonyms Bevacizumab biosimilar(Sino Cell Technologies), Recombinant humanized anti-VEGF monoclonal antibody(Sinocelltech Group), 重组人源化抗VEGF单抗 (神州细胞工程) + [4] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (27 Jun 2023), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Fallopian Tube Carcinoma | China | 27 Jun 2023 | |
Hepatocellular Carcinoma | China | 27 Jun 2023 | |
Metastatic Colorectal Carcinoma | China | 27 Jun 2023 | |
Non-squamous non-small cell lung cancer | China | 27 Jun 2023 | |
Ovarian Epithelial Carcinoma | China | 27 Jun 2023 | |
Primary peritoneal carcinoma | China | 27 Jun 2023 | |
Recurrent Glioblastoma | China | 27 Jun 2023 | |
Uterine Cervical Cancer | China | 27 Jun 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet age-related macular degeneration | Phase 3 | China | 14 Feb 2023 | |
Advanced Hepatocellular Carcinoma | Phase 3 | China | 11 Nov 2020 | |
Glioblastoma | Phase 3 | United States | - | |
Kidney Neoplasms | Phase 3 | United States | - | |
Kidney Neoplasms | Phase 3 | China | - | |
Ovarian Cancer | Phase 3 | United States | - | |
Non-Small Cell Lung Cancer | Phase 1 | China | 09 May 2018 |
Phase 3 | Non-squamous non-small cell lung cancer Maintenance | First line | 567 | vdpgnsunms(rzhixzslmc) = efjzpjmgjr zebzgdgpne (xsctndstiz, 46.66 - 58.55) View more | Similar | 04 Sep 2024 | ||
vdpgnsunms(rzhixzslmc) = jiyfdejkad zebzgdgpne (xsctndstiz, 46.47 - 58.47) View more | |||||||
Phase 3 | Advanced Hepatocellular Carcinoma First line | 346 | kkznsumcuq(hobdhkttjy) = vaitwdctge gzijrhxhyo (uummtkmxyi ) View more | Superior | 24 May 2024 | ||
kkznsumcuq(hobdhkttjy) = evlvabscfy gzijrhxhyo (uummtkmxyi ) View more |